Comparison: Ozempic vs Mounjaro
Both are reviewed at American Telehealth Review against published clinical evidence and FDA labeling.
Key differentiators
- Active ingredient: Ozempic = semaglutide; Mounjaro = tirzepatide.
- Mechanism: Ozempic GLP-1; Mounjaro dual GLP-1/GIP.
- HbA1c reduction: SURPASS-2 head-to-head: tirzepatide superior.
- Weight loss: tirzepatide ~47% greater than semaglutide 1 mg in SURPASS-2.
Other comparisons
Key facts, checked November 20, 2026
Both are FDA-approved for type 2 diabetes, not for weight management. The Ozempic injection label (semaglutide) also covers lowering cardiovascular risk and, after FLOW (NEJM 2024), slowing kidney decline in adults with type 2 diabetes and kidney disease. The Mounjaro label (tirzepatide) covers blood-sugar control in adults and children 10 and older. Their weight-management counterparts are Wegovy and Zepbound. In SURMOUNT-5 (NEJM 2025), adults without diabetes lost 20.2% on tirzepatide versus 13.7% on semaglutide at 72 weeks. FDA’s November 9, 2026 safety communication adds a NAION warning to both labels.